Scarica l'app Stockscreener
14.88
2.62%
0.38
Dopo l'orario di chiusura:
14.89
0.010
+0.07%
Precedente Chiudi:
$14.50
Aprire:
$14.5
Volume 24 ore:
1.13M
Relative Volume:
0.76
Capitalizzazione di mercato:
$2.11B
Reddito:
-
Utile/perdita netta:
$-42.76M
Rapporto P/E:
-46.38
EPS:
-0.3208
Flusso di cassa netto:
$-42.09M
1 W Prestazione:
+3.48%
1M Prestazione:
+12.81%
6M Prestazione:
+22.98%
1 anno Prestazione:
+125.45%
Intervallo 1D:
$14.30
$14.95
Intervallo di 1 settimana:
$13.36
$15.35
Portata 52W:
$5.3801
$16.12
Trevi Therapeutics Inc Stock (TRVI) Company Profile
Nome
Trevi Therapeutics Inc
Settore
Industria
Telefono
203-304-2499
Indirizzo
195 CHURCH STREET, NEW HAVEN, CT
Compare TRVI vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TRVI
Trevi Therapeutics Inc
|
14.88 | 2.06B | 0 | -42.76M | -42.09M | -0.3208 |
VRTX
Vertex Pharmaceuticals Inc
|
435.17 | 109.09B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
712.77 | 74.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
813.28 | 48.64B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
284.84 | 39.39B | 4.29B | 577.22M | 641.34M | 4.2086 |
ONC
Beone Medicines Ltd Adr
|
310.75 | 32.38B | 5.36B | 287.73M | 924.18M | 2.5229 |
Trevi Therapeutics Inc Stock (TRVI) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-13 | Iniziato | Leerink Partners | Outperform |
| 2025-08-21 | Iniziato | Morgan Stanley | Overweight |
| 2025-07-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-05-28 | Iniziato | H.C. Wainwright | Buy |
| 2025-03-10 | Reiterato | Needham | Buy |
| 2025-03-10 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2024-12-12 | Reiterato | H.C. Wainwright | Buy |
| 2024-09-09 | Ripresa | Leerink Partners | Outperform |
| 2024-08-30 | Iniziato | H.C. Wainwright | Buy |
| 2024-08-30 | Iniziato | Raymond James | Outperform |
| 2024-06-13 | Iniziato | Rodman & Renshaw | Buy |
| 2023-04-12 | Iniziato | B. Riley Securities | Buy |
| 2022-11-22 | Iniziato | SVB Leerink | Outperform |
| 2019-06-03 | Iniziato | BMO Capital Markets | Outperform |
| 2019-06-03 | Iniziato | Needham | Buy |
| 2019-06-03 | Iniziato | SVB Leerink | Outperform |
| 2019-06-03 | Iniziato | Stifel | Buy |
Mostra tutto
Trevi Therapeutics Inc Borsa (TRVI) Ultime notizie
Revenue per share of Trevi Therapeutics, Inc. – NASDAQ:TRVI - TradingView
Nan Fung Trinity HK Ltd. Boosts Holdings in Trevi Therapeutics, Inc. $TRVI - MarketBeat
F m Investments LLC Buys New Position in Trevi Therapeutics, Inc. $TRVI - MarketBeat
Comerica Bank Has $1.04 Million Stake in Trevi Therapeutics, Inc. $TRVI - MarketBeat
Trevi Therapeutics Maps Haduvio Chronic Cough Push, Sees Cash Runway Into 2030 - MarketBeat
Trevi Therapeutics (NASDAQ:TRVI) Stock Rating Lowered by Wall Street Zen - MarketBeat
Equities Analysts Offer Predictions for TRVI Q2 Earnings - MarketBeat
Trevi Therapeutics, Inc. (TRVI) Stock Analysis: A Biotech With 59.82% Potential Upside - DirectorsTalk Interviews
NEA stake in Trevi now 10.5% on share increase (TRVI) - Stock Titan
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q1 2026 Earnings Call Transcript - Insider Monkey
Research Analysts Set Expectations for TRVI FY2030 Earnings - MarketBeat
Trevi Therapeutics, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Why Trevi Therapeutics (TRVI) Is Up 5.9% After Extending Its Cash Runway Into 2030 - Yahoo Finance
FMR LLC shows 6.3% stake in Trevi Therapeutics (NASDAQ: TRVI) - Stock Titan
B. Riley Adjusts Trevi Therapeutics Price Target to $21 From $16, Maintains Buy Rating - marketscreener.com
Trevi Therapeutics (NASDAQ:TRVI) Price Target Lowered to $23.00 at Needham & Company LLC - MarketBeat
HC Wainwright Reaffirms Buy Rating for Trevi Therapeutics (NASDAQ:TRVI) - MarketBeat
Trevi Therapeutics Q1 2026 Earnings Call Transcript - MarketBeat
MSN Money - MSN
Stifel reiterates Buy rating on Trevi Therapeutics stock at $18 - Investing.com
Stifel reiterates Buy rating on Trevi Therapeutics stock at $18 By Investing.com - Investing.com Canada
Trevi Therapeutics Q1 Earnings Call Highlights - MarketBeat
Trevi Therapeutics : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q) - marketscreener.com
Earnings call transcript: Trevi Therapeutics Q1 2026 highlights cash boost and clinical progress - Investing.com UK
TRVI: Cash runway into 2030 supports multiple advancing chronic cough trials and new patent coverage - TradingView
Trevi Therapeutics Q1 net loss widens as R&D costs rise - TradingView
Trevi Therapeutics (NASDAQ:TRVI) Releases Quarterly Earnings Results, Misses Expectations By $0.02 EPS - MarketBeat
Q1 2026 Trevi Therapeutics Inc Earnings Call Transcript - GuruFocus
Trevi Therapeutics (NASDAQ: TRVI) raises $162M, funds cough trials - Stock Titan
Trevi Therapeutics (NASDAQ: TRVI) widens Q1 loss and raises $173M - Stock Titan
Fresh $162M gives Trevi runway into 2030 ahead of Phase 3 cough trials - Stock Titan
Trevi Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
BRIEF-Trevi Therapeutics Q1 Net Income USD -13.192 Million - TradingView
Pictet Asset Management Holding SA Purchases 1,520,754 Shares of Trevi Therapeutics, Inc. $TRVI - MarketBeat
Trevi Therapeutics Announces Oral Presentation and Multiple Posters Accepted at the American Thoracic Society (ATS) 2026 International Conference - The Manila Times
Trevi Therapeutics, Inc. Announces Oral Nalbuphine Extended-Release Clinical Trial Results And Presentations - marketscreener.com
Trevi Therapeutics (TRVI) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Trevi Therapeutics (TRVI.US) is scheduled to release its earnings report after the market closes on May 5. - Moomoo
TRVI stock’s five-day rally pushes it to an all-time high – here’s what’s happening - MSN
Trevi Therapeutics Closes $173 Million Public Offering - Global Legal Chronicle
Clinical-stage biotech Trevi sets May 5 webcast for Q1 results - Stock Titan
Trevi Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 5, 2026 - marketscreener.com
Trevi Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Corporate Update on November 6, 2024 - Quantisnow
Trevi Therapeutics Inc Azioni (TRVI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.70%
2.51%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):